Aragen Life Sciences IPO Legal Advisors: CAM, TT&A, Trilegal Guide ₹800 Cr Offering

• Aragen Life Sciences Limited has proposed an initial public offering, comprising a ₹800 crore fresh issue and an offer for sale of up to 27,329,192 equity shares.
• Cyril Amarchand Mangaldas is advising Aragen Life Sciences, with Yash J. Ashar and Tanvi Kini leading the team.
• TT&A is counseling selling shareholders Leo Investment Holdings Pte. Ltd. and Quadria Capital India Fund III, led by Abhinav Kumar and Indira Satish.
• Trilegal is advising the Book Running Lead Managers, including Axis Capital, Citigroup Global, Goldman Sachs, and JM Financial, with Bhakta Patnaik and Albin Thomas as lead partners.
• Aragen Life Sciences is recognized as the largest CRDMO among assessed Indian peers by solutions offered across the drug development value chain as of March 31, 2026.

The allocation of roles among these top Indian law firms in the Aragen Life Sciences IPO demonstrates the specialized expertise required for such a significant capital markets event.

Aragen Life Sciences Limited has put forth a proposal for an initial public offering (IPO) of its equity shares. This significant market debut is structured to include both a fresh issuance of shares and an offer for sale by existing shareholders. The fresh issue component is slated to raise an aggregate of ₹800 crore, injecting new capital into the company. Concurrently, the offer for sale will see up to 27,329,192 equity shares divested by various selling shareholders.

This proposed public offering marks a notable development for Aragen Life Sciences, a prominent player in the Contract Research, Development, and Manufacturing Organization (CRDMO) sector. The company's move to go public underscores its growth trajectory and ambition within the life sciences industry, seeking to leverage capital markets for its strategic objectives. The dual structure of the IPO, combining fresh capital infusion with an opportunity for early investors to exit, is a common approach for companies of this scale.

The intricate legal framework surrounding Aragen Life Sciences' proposed IPO has engaged several leading Indian law firms, each advising different parties involved in the transaction. Cyril Amarchand Mangaldas (CAM) is providing legal counsel to Aragen Life Sciences itself, guiding the company through the complexities of its public offering. The team at CAM is spearheaded by Senior Partner Yash J. Ashar and Partner Tanvi Kini, with crucial support from Senior Associate Surya Rajkumar and Associates Tejaswi Sade, Mohammed Khadri, Maria Palamattom, and Akshita Dhawan. Their involvement highlights the critical role of legal advisors in navigating corporate finance transactions of this magnitude, particularly for the Aragen Life Sciences IPO legal advisors.

Separately, TT&A has been enlisted to advise the selling shareholders participating in the offer for sale. Specifically, TT&A is representing Leo Investment Holdings Pte. Ltd. and Quadria Capital India Fund III, both identified as affiliate entities of Quadria. The legal team from TT&A overseeing this aspect of the IPO is led by Partner Abhinav Kumar and Senior Associate Indira Satish. Their mandate involves ensuring the smooth divestment of equity shares by these key investors, marking TT&A's role in the Aragen Life Sciences IPO.

Furthermore, Trilegal is providing legal advice to the consortium of Book Running Lead Managers (BRLMs) for the IPO. This group of financial institutions includes Axis Capital, Citigroup Global, Goldman Sachs, and JM Financial. Trilegal's engagement underscores the comprehensive legal support required across all facets of a major public listing. The Trilegal team is jointly led by Partners Bhakta Patnaik and Albin Thomas, with additional contributions from Counsel Bhargavi Mahajan and Associates Janhavi Shah, Snehal Kaushal, Tushar Chitlangia, Mohak Agarwal, and Harshali Srivastava. The allocation of roles among these top Indian law firms in the Aragen Life Sciences IPO demonstrates the specialized expertise required for such a significant capital markets event, with Trilegal acting as Aragen IPO counsel.

Aragen Life Sciences holds a distinguished position within the Indian Contract Research, Development, and Manufacturing Organization (CRDMO) landscape. According to assessments of Indian peers, the company stands as the largest CRDMO in terms of the sheer number of solutions it offers across the entire drug development value chain, a status maintained as of March 31, 2026. This leadership position underscores Aragen's comprehensive capabilities and its integral role in the pharmaceutical and biotechnology sectors.

As one of India’s foremost CRDMO platforms, Aragen provides an extensive array of solutions that span the entire drug development lifecycle. This includes expertise in both small molecules and biologics, catering to a broad spectrum of pharmaceutical research and manufacturing needs. The proposed Aragen Life Sciences ₹800 crore IPO, therefore, not only represents a significant financial event for Aragen but also offers a window into the robust and expanding capital markets activity within India's life sciences industry, particularly for specialized CRDMOs. The involvement of top legal firms in this transaction further emphasizes the growing importance and complexity of transactions in this dynamic sector, providing insight into India CRDMO IPO legal advice.

Lawyers can observe the allocation of roles among top Indian law firms in a significant life sciences IPO, providing insight into deal structuring and identifying active counsel for similar future transactions, particularly within the CRDMO sector. This also highlights the growing M&A and capital markets activity in the pharmaceutical and life sciences industry.

Source: Reporting based on market intelligence.